Preferred Drug List announcement

Preferred Drug List Announcement

MO HealthNet Division (MHD) is continuing the state-specific Preferred Drug List (PDL) evaluation process. Drug/Drug classes for review for the upcoming quarter are identified at each of the quarterly meetings of the Drug Prior Authorization Committee and also posted on the Division's web page at shortly following each meeting.

MO HealthNet Division's clinical team will conduct the clinical reviews of the drug products under evaluation each quarter. For preferred status consideration for your product, a more detailed review request should be presented to MHD. All clinical information for consideration should be forwarded to Joshua Moore at Joshua.S.Moore@dss. or call (573) 751-6961. These submissions should generally follow the AMCP guideline format. Financial evaluations for these therapeutic class reviews are conducted by Conduent State HealthCare, LLC. Companies wishing to discuss opportunities for supplemental rebates should contact Conduent State HealthCare, LLC at (804) 965-8117.

If you have any questions concerning the PDL submission process, or the policy surrounding the process, feel free to contact the pharmacy program at MHD.ClinicalServices@dss. or (573) 751-6961. If a public presentation is desired, please contact Carmen Burton at Carmen.M.Burton@dss. or call (573) 751-6961. The Drug PA Committee will convene at 10:00 a.m. on Thursday, September 17, 2020.

Drug Therapeutic Class Name

? ACE Inhibitors/CCB Combination Agents

? ACE Inhibitors & ACE Inhibitor Diuretic Combination Agents

? ADHD: Amphetamines, Long Acting ? ADHD: Amphetamines, Short Acting ? ADHD: Methylphenidate, Long Acting ? ADHD: Methylphenidate, Short Acting ? ADHD: Non-Stimulant Agents ? Anticoagulant Agents, Oral &

Subcutaneous ? Anticonvulsants, Rescue Agents ? Antiplatelet Agents ? ARB/CCB Combination Agents ? ARB & ARB/Diuretic Combination

Agents ? Beta Blockers & Beta Blockers/Diuretic

Combination Agents ? CCB Agents, Dihydropyridines ? CCB Agents, Non-Dihydropyridines ? Direct Renin Inhibitors & Combination

Agents ? Dry Eye Disease Agents

? Homozygous Familial Hypercholesterolemia (HFHC) Agents

? Niacin Derivatives ? PAH Agents: Inhaled/Injectable ? PAH Agents: Endothelin Receptor

Antagonists (ETRAs), Oral ? PAH Agents: Phosphodiesterase-5

(PDE5) Inhibitors & Soluble Guanylate Cyclase (SGC) Stimulators, Oral ? PAH Agents: Prostacyclin Pathway Agonists, Oral ? Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Binders ? Proton Pump Inhibitors ? Statins (HMG Co-A Reductase Inhibitors) & Combination Agents ? Spinal Muscular Atrophy Agents ? Sympatholytic Agents ? Triglyceride Lowering Agents

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download